#CancerVaccine is an active hashtag on Bluesky. In the last 30 days, 11 people shared 15 posts with it — around 1 a day. Activity is down 100% versus the previous week, peaking on Aug 27 with 3 posts.
www.livescience.com
'Universal' cancer vaccine heading to human trials could be useful for 'all forms of cancer'
A new mRNA-based vaccine triggers a response from the innate immune system to help arm the body against cancer, a mouse study finds. It's now in early human trials.
doi.org
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer | Nature
A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA–lipoplex vaccines against somatic mutation-derived neoantigens may solve this challenge in pancreatic ductal adenocarcinoma (PDAC), a lethal cancer with few mutations. At an extended 3.2-year median follow-up from a phase 1 trial of surgery, atezolizumab (PD-L1 inhibitory antibody), autogene cevumeran1 (individualized neoantigen vaccine with backbone-optimized uridine mRNA–lipoplex nanoparticles) and modified (m) FOLFIRINOX (chemotherapy) in patients with PDAC, we find that responders with vaccine-induced T cells (n = 8) have prolonged recurrence-free survival (RFS; median not reached) compared with non-responders without vaccine-induced T cells (n = 8; median RFS 13.4 months; P = 0.007). In responders, autogene cevumeran induces CD8+ T cell clones with an average estimated lifespan of 7.7 years (range 1.5 to roughly 100 years), with a
www.skepticalraptor.com
Study links COVID mRNA vaccine with longer cancer survival
A study revealed that lung cancer and melanoma patients who received a COVID mRNA vaccine had nearly double the survival rate.
oncodaily.com
Bernard A. Fox: Cancer Vaccines and Combination Immunotherapy - OncoDaily
Bernard A. Fox: Cancer Vaccines and Combination Immunotherapy / Bernard A. Fox, cancer, cancer vaccines, OncoDaily, Oncology, Paolo A. Ascierto
oncodaily.com
Cancer Vaccines Improve Survival in Advanced Non-Small-Cell-Lung-Cancer After First-Line Therapy - OncoDaily
Cancer vaccines improve overall survival in advanced NSCLC post–first-line therapy, with favorable safety and predictive immune biomarkers.
www.nature.com
Recent advances in therapeutic cancer vaccines - Nature Reviews Cancer
Cancer prevention vaccines have reduced cancer-related mortalities, yet therapeutic cancer vaccine development and clinical translation continues to face challenges. Here, Zaidi, Jaffee and Yarchoan s...
Nature Reviews Cancer @natrevcancer.nature.com
Our July issue is LIVE! 🌞🥵🏖️ It features articles on: - Targeted protein degradation for cancer therapy - Advances in therapeutic cancer vaccines - The TGFβ paradox in HPV-driven cancer - The paths to metastasis Happy reading! 👇 📖 https://www.nature.c...
oncodaily.com
Memorial Sloan Kettering Cancer Center Oncologists Co-Lead Study on KRAS-Targeted Cancer Vaccine - OncoDaily
Memorial Sloan Kettering Cancer Center Oncologists Co-Lead Study on KRAS-Targeted Cancer Vaccine / Alexis D. Leal, cancer, cancer vaccine, Christopher M.
www.limfic.com
Writer Fuel: We Might Be Close to a “Universal Cancer Vaccine”
A universal cancer vaccine in development could help rev up the immune system against tumors and supercharge the effects of existing cancer therapies, an animal study suggests. Similar to vaccines for...
www.cambridge.org
Gregory J. Morgan, Cancer Virus Hunters: A History of Tumor Virology Baltimore: Johns Hopkins University Press, 2022. Pp. 392. ISBN 978-1-4214-4401-7. $50.00 (hardcover). | The British Journal for the...
Gregory J. Morgan, Cancer Virus Hunters: A History of Tumor Virology Baltimore: Johns Hopkins University Press, 2022. Pp. 392. ISBN 978-1-4214-4401-7. $50.00 (hardcover).
www.ucsf.edu
Why Novel Cancer Vaccine Tested at UCSF Marks New Treatment Era
UCSF researchers helped test the first personalized mRNA cancer vaccine shown to prevent melanoma from returning or spreading, marking a breakthrough in cancer treatment.
www.newsmason.com
www.newsmason.com
dlvr.it
Moderna turns its cancer vaccine rally into $2 billion in fresh capital
A week after its stock surged 177% on promising mRNA cancer vaccine data, Moderna is cashing in on that momentum with a $2 billion convertible debt offering. The move lets the company fund its cancer drug push while keeping share dilution in check — a smart play when your stock is near a multi-year high.
dlvr.it
Moderna turns its cancer vaccine rally into $2 billion in fresh capital
A week after its stock surged 177% on promising mRNA cancer vaccine data, Moderna is cashing in on that momentum with a $2 billion convertible debt offering. The move lets the company fund its cancer drug push while keeping share dilution in check — a smart play when your stock is near a multi-year high.
www.newsmason.com
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.
